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Purpose: The aim of this study was to assess the role of the two markers, S100P and IMP3, in differenti-
ating between pancreatic ductal adenocarcinoma (PDA) and non-neoplastic pancreatic tissue in (fine nee-
dle aspiration cytology) FNAC.
Patients and methods: This is a retrospective study that included 72 cases presented with pancreatic mass,
where endoscopic guided FNAC was taken from pancreatic lesions. The final histopathologic diagnosis
was considered the gold standard. Cell blocks were stained with anti S100P, and IMP3. Nuclear
immunoreactivity with or without cytoplasmic staining for the first marker, and cytoplasmic staining
for the second marker was considered specific.
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and total accu-
racy of the two markers, as well as the combined accuracy of both markers were calculated.
Results: S100P achieved 96.4% sensitivity, 93.3% specificity, 98.2% PPV, 87.5% NPV and 95.8% total accu-
racy, while IMP3 achieved 91.2% sensitivity, 86.7% specificity, 96.2% PPV, 72.2% NPV and 90.3% total accu-
racy for PDA.
Both markers showed a total combined accuracy of 89%.
S100P showed strong and diffuse staining pattern in most of cases, while the staining pattern for IMP3
was moderate and focal in most of cases.
Conclusion: Both markers were sensitive and specific for diagnosis of PDA. The staining pattern for S100P
was easier to evaluate than IMP3.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pancreatic cancer is the fourth cause of cancer death in the
Western world, and in spite of efforts done to advance knowledge
and the treatment of this type of cancer, mortality rates have
remained relatively high [1].
The 5-year survival rate of pancreatic cancer is estimated to be
8%. Such low survival rate is attributed to the advanced stage at
which the cancer is diagnosed [2].
Generally, the diagnosis is established using computerized
tomography (CT), endoscopic ultrasound (EUS) or endoscopic ret-
rograde cholangiopancreatography (ERCP) with histological (or
cytological) confirmation. Traditionally, CT and trans-abdominal
ultrasonography (US) have been used to guide the aspiration of apancreatic mass. Recently, endoscopic ultrasound (EUS) has been
introduced as an alternative to CT/US guidance, because of superior
imaging of the pancreas achieved by EUS [3].
The reported range of sensitivity, specificity, and accuracy of
EUS-FNA for pancreatic lesions is 64–94%, 71–100%, and 78–95%,
respectively [4].
PDA and its variants account for approximately 85% of all pan-
creatic neoplasms. Distinguishing PDA from reactive non-
neoplastic pancreatic ducts, such distinction is challenging, espe-
cially in small biopsies and FNAC due to cytologic overlap between
neoplastic and reactive processes. Numerous immunohistochemi-
cal (IHC) markers have been reported as useful markers for such
differentiation [5].
Using serial analysis of gene expression, 2 new markers of PDA
were discovered, S100P and Insulin-like growth factor-2 (IGF-2)
mRNA binding protein 3(IMP3) where their value in the diagnosis
of PDA by IHC studies was confirmed [6].
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protein, it is an oncofetal protein that regulates insulin-like growth
factor II (IGF-II) transcripts during embryogenesis and re-
expressed later in a proportion of neoplastic cells from various
tumor types, including lung squamous cell carcinoma, lung and
pancreatic adenocarcinoma, malignant melanoma, mesothelioma
and carcinomas of different organs. Over-expression of IMP3 in
malignant relative to non-malignant pancreatic tissue is well-
documented. In addition, a high expression of IMP3 was found in
poorly differentiated, grade 3 pancreatic tumors [7].
S100P belongs to the S100 family of calcium binding proteins. It
is a 95-amino-acid protein that was first purified from the placenta
[8]. Several recent studies have found that several S100-related
proteins, including S100P, S100A6, and S100A4, are overexpressed
in PDA. In addition to PDA, S100P expression has been found in
various tumors [9].
In a recent study on pancreatic benign and malignant lesions,
anti-S100P nuclear or nuclear/cytoplasmic immunostaining can
be seen in 100% PDA of fine needle aspiration (FNA) biopsy. On
the other hand, none of benign pancreatic ducts exhibited reactiv-
ity for S100P [10].
While the expression of S100P in PDA has been documented in
surgical specimens, only few reports have tested the use of S100P
as a diagnostic marker for PDA in FNAB [11].
The present study aimed at evaluating the role of the two mark-
ers, IMP3 and S100P, in differentiating PDA from non-neoplastic
pancreatic cells in fine needle aspiration specimens.Fig. 1. FNAC from a case diagnosed as suspicious for malignancy showing sheet of
irregularly arranged ductal epithelial cells having hyperchromatic enlarged nuclei,
and marked pleomorphism (papanicolaou stain 100).Patients and methods
The present study included 72 patients who presented to
National Cancer Institute (NCI) by pancreatic lesions, these cases
were referred from Radiology Department to Cytopathology Unit,
Pathology Department, NCI, Cairo University, during the period
from March 2013 to April 2015. Patients’ files were reviewed and
data related to age and sex of the patients, site, number and size
of lesions, radiological information, routinely done tumor marker
serum level, and any other relevant data were recorded.
The lesions were obtained by EUS-FNAC where endoscopists
placed powerful ultrasound transducers (echoendoscopes) against
the gastric or duodenal wall, in close position to the pancreatic
lesions, (a transduodenal approach was used for the lesions pre-
sent in the head of the pancreas, and transgastric approach when
the lesion was located in the body or the tail), a small gauge needle
was passed through the wall of the gastrointestinal tract and into
the pancreatic mass, the size of the needle used ranged from 25
to 19 gauge needles, 5–6 separate passes of pancreatic lesions were
done to achieve maximal accuracy. A cytopathologist was available
for On-site evaluation to assess specimen adequacy for each case.
For each case, six smear slides and material for cell blocks were
prepared. The smears were immediately fixed in 95% ethyl alcohol.
The slides and cell blocks were sent to Cytopathology Unit. The
smears were left in alcohol for 30 min at room temperature and
subsequently stained with modified Papanicolaou stains [12]. The
cases were diagnosed as either pancreatic adenocarcinoma,
chronic pancreatitis, or suspicious for malignancy. The cases diag-
nosed as adenocarcinoma showed moderate to highly cellular
smears of isolated and crowded sheets of disordered ductal epithe-
lial cells (drunken honey comb), having enlarged nuclei with irreg-
ular nuclear contours, pleomorphism, irregularly distributed
chromatin, and abundant mitotic figures. On the other hand, cases
diagnosed as chronic pancreatitis showed lympho-histiocytic infil-
trate or fibrosis according to the stage, the ductal cells are arranged
in flat sheets of evenly spaced nuclei showing smooth round con-
tours, evenly distributed fine granular chromatin, inconspicuousnucleoli, and well defined cytoplasmic boundaries. While the sus-
picious cases revealed overlapping morphologic features.
Cases showing hypocellularity, or bad quality (11 cases) were
considered inadequate and excluded from the study.
Tissue biopsy from pancreatic lesion was considered the gold
standard.
From each cell block, one hematoxylin and eosin stained slide
was prepared for evaluation of cellular adequacy, additional 2 sec-
tions were prepared on positively charged glass slides for applica-
tion of both markers. anti-S 100 P which is concentrated, (dilution
1:100), rabbit monoclonal antibodies from Epitomic (USA) (clone:
EP234), and anti-IMP3, concentrated (dilution 1:100), mouse mon-
oclonal antibody from Dako (USA) (clone 96.1) were applied using
the avidin biotin peroxidase technique; the reaction was detected
using diaminobenzidine with hydrogen peroxide. All slides were
counterstained with hematoxylin. Appropriate positive control
(Pancreatic ductal adenocarcinoma for S100P, and normal squa-
mous epithelium for IMP3) and negative controls (by substituting
PBS for the primary antibodies) were used.
Cases were considered positive for S100P if tumor cells showed
nuclear with or without cytoplasmin staining, and for IMP3 if it
showed cytoplasmic reactivity in more than 5% of malignant cells.
Staining intensity (weak, moderate, or strong) and distribution
(focal or diffuse) were evaluated. Staining was considered focal if
fewer than 25% of cells were positive, and diffuse if more than
25% were positive.
Sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), total accuracy, and combined total accu-
racy of both markers, were calculated.Results
In the present study, we included 72 patients who presented
with pancreatic lesions, of which, 48 (66.7%) were males, and 24
(33.3%) were females, with a male to female ratio of 2:1.
The age of the included patients ranged from 43 to 79, with a
mean of 57.7, and a median of 57.
Forty-four (61.1%) of the lesions were located in the pancreatic
head, while 28 (38.9%) were located in the body.
The size of pancreatic lesions ranged from 2.5 cm to5.8 cm, with
a median of 3.8.
Thirty-three (45.8%) cases were diagnosed cytologically as pan-
creatic adenocarcinoma, 12 (16.7%) as benign or reactive, and 27
(37.5%) cases as atypical or suspicious for malignancy (Fig. 1)
Table 1.
Table 1
Distribution of the cases according to cytologic diagnosis.
Cytologic diagnosis NO %
Ductal adenocarcinoma 33 45.8
Suspicious or atypical 27 37.5
Chronic pancreatitis 12 16.7
Total 72 100
Fig. 3. Cell block from a case diagnosed cytologically as suspicious for malignancy
and proved to be positive, showing positive cytoplasmic staining for IMP3 (400).
Fig. 4. Cell block from a case of PDA showing positive nuclear expression for S100P
(400).
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was positive in 31(93.9%) cases of PDA (Fig. 2), 21 (77.8%) of suspi-
cious cases (Fig. 3), and 2 (16.7%) cases of chronic pancreatitis. On
the other hand, 31(93.3%) cases of PDA (Fig. 4), 24 (88.9%) suspi-
cious cases, and 1 (8.3%) reactive case showed positive nuclear
expression for S100P Table 2.
After correlation of the included cases with the gold standards
used in the current study (surgical biopsy specimen (15 cases),
tumor marker serum level (72 cases), and clinical follow up (52
cases)), it was found that all cases of PDA were proved to be malig-
nant, and all cases of chronic pancreatitis were benign, while of the
27 suspicious cases, 24 (88.9%) were confirmed as PDA, and the
remaining 3 (11.1%) cases as chronic pancreatitis.
Of the 24 suspicious cases proved to be malignant, IMP3 was
positive in 21 (87.5%) cases, and S100P in 24 (100%) cases. Thus,
IMP3 showed total positivity in 52/57 cases (31cytologically malig-
nant cases and 21 cytologically suspicious proved to be malignant)
of PDA (91.2%), and negative expression in 13/15 benign cases
(86.7%), achieving a total sensitivity of 91.2%, and a total specificity
of 86.7%, on the other hand, S100 was totally positive in 55/57
malignant cases (96.4%), (31 cytologically malignant cases and 24
cytologically suspicious proved to be malignant), and negative in
14/15 benign cases (93.3%), thus the overall sensitivity and speci-
ficity achieved by S100P were 96.4%, and 93.3%, respectively
Table 3.
The 57 cases of PDA (including 33 cytologically diagnosed cases,
and 24 cytologically suspicious cases proved later on to be malig-
nant) were classified into 3 groups: 20 (35.1%) well differentiated
cases, 22 (38.6%) moderately differentiated and 15 (26.3%) poorly
differentiated cases.
After exclusion of the cases where both S100P and IMP3 showed
false positive or false negative expression 8/72 (11%), both markers
could accurately diagnose 64/72 cases, thus showing a total accu-
racy of 89%.
Most of PDA cases showed strong and diffuse staining pattern
for S100P, (69.1%, and 89.1%) respectively, while focal (Fig. 5) andFig. 2. Cell clock from a case of PDA showing positive cytoplasmic staining for IMP3
(400).moderate expression for IMP3 was detected in most of cases
(61.5%, and 63.5%, respectively) Tables 4 and 5.Discussion
Pancreatic cancer is a highly lethal neoplasm; it represents the
fourth leading cause of cancer related death in the United States. It
is usually silent until late in the course of disease [13].
Several methods are used as standard nonsurgical methods to
get tissue biopsy, including Endoscopic retrograde cholangiopan-
creatography (ERCP) brushing, CT-guided biopsies, and trans
abdominal ultrasound (US), however, a high false-negative rate
has been reported [14].
EUS-FNAB is relatively new, accurate, minimally invasive and
safe method for obtaining tissue for diagnosis of patients with pan-
creatic lesions, it is the investigation of choice since pancreas is
inaccessible, and both wide bore needle and open biopsy have a
high morbidity. In addition, surgical approach is not indicated for
benign disease, and most pancreatic carcinomas are in-operable
at the time of diagnosis [15].
Interpreting FNA or small biopsy specimens is not always
straight forward for the diagnosis of PDA, especially when the
tumor is well-differentiated due to subtle cytologic atypia and
overlapping cytologic features between neoplastic and reactive
ductal epithelium. In spite of the presence of some cytomorpho-
logic features that may provide a diagnostic clue for well
Table 2
Markers expression of the included cases.
Cytologic diagnosis NO IMP3 S100P
Positive Negative Positive Negative
PDAC 33 31(93.9%) 2(6.1%) 31(93.9%) 2(6.1%)
Suspicious 27 21(77.8%) 6(22.2%) 24(88.9%) 3(11.1%)
Chronic pancreatitis 12 2(16.7%) 10(83.3%) 1(8.3%) 11(91.7%)
Table 3
Sensitivity, specificity, PPV, NPV, and accuracy of both markers.
Marker Sensitivity Specificity PPV NPV Total accuracy
IMP3 52/57(91.2%) 13/15(86.7%) 52/54(96.2%) 13/18(72.2%) 65/72(90.3%)
S100P 55/57(96.4%) 14/14(93.3%) 55/56(98.2%) 14/16(87.5%) 69/72(95.8%)
Fig. 5. Cell block from a case of PDA showing focal cytoplasmic staining for IMP3
(200).
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pattern of epithelial groups, and variable degrees of anisonucleosis
and nuclear membrane irregularity of epithelial cells, the distinc-
tion between PDA and reactive epithelial tissue is impossible in
some conditions. Furthermore, superimposed chronic pancreatitis
and pancreatic intraepithelial neoplasia may complicate the diag-
nosis [16].
Immunohistochemistry has become an important ancillary
technique for diagnosis and classification of pancreatic neoplasms.
PDA expresses a large number of proteins that can aid in establish-
ing the diagnosis of cancer, these tissue markers can be detected
using number of available antibodies [17].
The diagnostic sensitivity and specificity of FNAC have been
improved due to discovery of number of immunohistochemical
markers. In addition to already established antibodies, new mark-
ers such as mesothelin, prostate stem cell antigen (PSCA), claudin
4, and those targeting K-ras, have been reported to be useful, but
the findings were not definitive [18].
Lok et al., have found that a panel of 2 recently described mark-
ers S100P and IMP3, achieved almost 100% sensitivity and speci-
ficity in detecting pancreatic adenocarcinoma [19].Table 4
S100P expression among different grades of PDAC.
Different grades Total S100P
Intensity
Strong
Well differentiated 19 14
Moderately differentiated 21 15
Poorly differentiated 15 9Recent studies have documented that several S100-related pro-
teins, including S100P, S100A6, and S100A4, are overexpressed in
PDA. S100P is a 95-amino-acid protein that is first isolated from
the placental tissue; it is related to the S100 protein family of cal-
cium binding proteins. S100P overexpression is associated with a
poor clinical outcome [11].
The use of S100P has several advantages over previously men-
tioned markers as mesothelin, PSCA, and KOC, including that it is
a nuclear marker so can be easily interpreted especially in small
biopsies and cytologic smear. In addition it can be used with
destained alcohol-fixed smears with few technical problems as
cell blocks are not always possible to obtain. Dang and col-
leagues have examined the application of S100P on destained
smears of 6 suspicious cases proved later on to be malignant,
where the marker showed positive staining results in all cases.
Moreover, S100P gives 100% sensitivity in relatively few numbers
of cells [10].
In the current work, the sensitivity and specificity achieved by
S100P were 96.4% and 94.3%, respectively.
Our results have fallen within the range of sensitivity, and
specificity achieved by the marker in literature, where the sensitiv-
ity ranged from 56% to 100%, and specificity from 67% to 100%
[10,20–23].
Lin et al., have found that S100A6 and S100A4 were positive in
98% and 73% of PDA, respectively, however, 20% of benign duct also
showed nuclear or nuclear and cytoplasm positivity for these two
markers, so they concluded that both markers were less appropri-
ate than S100P for diagnosis of PDA [10].
Deng et al., have reported 100% sensitivity in all suspicious
cases proved to be malignant. In a similar manner, S100P showed
positivity in all suspicious cases proved later on to be malignant
in our study [20].
S100P achieved 95.8% diagnostic accuracy in the present work.
In their study, Deng et al. have reported a higher diagnostic accu-
racy (100%) for S100P than other tumor markers reported in liter-
ature [20].
Similar to our study where S100P showed strong and diffuse
staining pattern in 69%, and 89% of cases, respectively, most cases
studied by Deng et al. showed strong and diffuse staining, with noDistribution
Moderate Weak Focal Diffuse
4 1 2 17
4 2 2 19
3 3 2 13
Table 5
IMP3 expression among different grades of PDAC.
Different grades Total IMP3
Intensity Distribution
Strong Moderate Weak Focal Diffuse
Well differentiated 17 5 11 1 11 6
Moderately differentiated 22 6 13 3 14 8
Poorly differentiated 13 2 8 3 8 5
N.E. Ezzat et al. / Journal of the Egyptian National Cancer Institute 28 (2016) 229–234 233difference in staining pattern and distribution among different
grades [20].
As reported in previous several studies, a background staining
for S100P was noticed in some cases of PDA, this can occur in back-
ground stromal cells, inflammatory cells, and endothelial cells.
Since S100A6 doesn’t show such background staining, it can be
used as substitute, unfortunately, weak nuclear and cytoplasmic
staining for S100A6 can be seen in normal/reactive pancreatic
ducts, while normal/reactive pancreatic ducts were either negative
or showed only cytoplasmic positivity for S100P [10].
In addition to overexpression of S100p in carcinoma and dys-
plastic cells, the histologically benign biliary epithelium also
expresses this antibody. However, S100P expression in benign
epithelial cells is focal, and its intensity is weak to intermediate,
usually with weak cytoplasmic staining in comparison to stronger
nuclear reactivity. While, the staining pattern seen in carcinoma
and dysplastic cells is equal and strongly stained the nuclei and
cytoplasm.
IMP3 is an oncofetal protein that is involved in the malignancy
of PDA. Several previous studies have shown that IMP3 is over
expressed in PDA. It was found that IMP3 expression is an indepen-
dent predictor factor of overall survival, and correlated with poor
prognosis in patients with pancreatic cancer [7].
In the current work, IMP3 achieved a sensitivity of 91.2% and a
specificity of 86.7% for diagnosis of PDA.
Our figure regarding the sensitivity agreed with that reported in
previous studies, where the sensitivity ranged from 86.6% to 97%
[18,22,24,26–28].
On the other hand, the specificity achieved in our study was
nearly similar to that detected by Wacheter et al. (88.4%) [25],
while it was lower than that reported in other studies, where the
specificity ranged from 90% to 100% [22,24,27].
In the present study, in contrast to S100P that showed a strong
and diffuse staining pattern in most of cases, IMP3 showed a mod-
erate and focal staining in most of cases. Yantiss et al. agreed with
us where they have also found that staining for IMP3 was moder-
ate in most of cases, where it was weak in (18%), moderate in (45%)
and strong in (36%) of the cases [18].
In a similar manner, Liu et al. have noticed that cytoplasmic
staining for IMP-3 was weaker than S100P [22].
The difference in the results between ours and other studies
may refer to several factors, including the differences in study
designs, sample size, statistical method used, using different
clones, and difference in interpretation. Another factor is that some
studies used histological assessment as a gold standard, while in
others, patients diagnosis was based on clinical course, together
with radiological and laboratories findings.
In the current work, both markers achieved a total combined
accuracy of 89%, Luis and his colleagues agreed with our results
where they have reported a 90% total accuracy for both markers
[22].
From the present work we concluded that both markers used in
the present work, S100P and IMP3, were sensitive and specific
markers for confirming diagnosis of PDA on cell blocks derived
from EUS guided FNAC. The two markers used in our study canaccurately classify 89% of cases as either benign or malignant.
S100P was more sensitive and specific than IMP3. The interpreta-
tion of S100P results was easier than IMP3 as it showed diffuse
and strong staining pattern in most cases.Conflict of interest
There are no conflicts of interest.References
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